Compare ZNTL & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZNTL | NPCT |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 306.8M |
| IPO Year | 2020 | N/A |
| Metric | ZNTL | NPCT |
|---|---|---|
| Price | $1.35 | $10.22 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.87 | N/A |
| AVG Volume (30 Days) | ★ 761.7K | 107.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,865,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $8.58 |
| 52 Week High | $3.33 | $10.63 |
| Indicator | ZNTL | NPCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 34.91 |
| Support Level | $1.34 | $10.15 |
| Resistance Level | $1.46 | $10.26 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 10.00 | 19.84 |
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.